Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504140 · ClinicalTrials.gov registry record · Phase 2
Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00504140: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00504140 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00504140, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To determine the efficacy of combining Interferon Alpha (IFN) with etoposide for the treatment of relapsed osteosarcoma. 2. To determine if IFN alters the plasma pharmacokinetics of etoposide. 3. To determine the toxicities of IFN and etoposide when administered together. 4. To determine IFN blood levels following combination therapy.
Interventions
- DRUG Etoposide
- DRUG Interferon Alpha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1996-11 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00504140
The ClinicalTrials.gov registry entry for NCT00504140 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Etoposide is the first listed.
NCT00504140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00504140 about?
NCT00504140 is a clinical study titled "Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma". Primary Objectives: 1. To determine the efficacy of combining Interferon Alpha (IFN) with etoposide for the treatment of relapsed osteosarcoma. 2. To determine if IFN alters the plasma pharmacokinetics of etoposide. 3. To determine the toxicities of IFN and etoposide when administered together. 4. ...
What is the current status of trial NCT00504140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1996-11. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00504140?
The interventions under investigation include: Etoposide (DRUG), Interferon Alpha (DRUG).
Who is sponsoring clinical trial NCT00504140?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.